Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
AssigneeNovo Nordisk HealthCare A/G
InventorsMirella Ezban, Lars Petersen, Agneta Siegbahn
Life of this patent
Estimating the term…
Abstract
The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.
Claims3
A method of treating burns in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for treating burns.
A method of treating inflammation in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for treating inflammation.
A method for inducing or enhancing the regeneration of vessel walls in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for inducing or enhancing the regeneration of vessel walls.
Dependencies are inferred from the claim text.